PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLutetium (177lu) oxodotreotide
Lutetium dotatate lu-177
EndolucinBeta, Lumark (lutetium dotatate lu-177) is an unknown pharmaceutical. Lutetium dotatate lu-177 was first approved as Lumark on 2015-06-18. It has been approved in Europe to treat radionuclide imaging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
diagnosisD003933
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.81725711154
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carcinoid tumorD002276D3A.00325
Gastro-enteropancreatic neuroendocrine tumor1123
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine carcinomaD018278166
Pancreatic neoplasmsD010190EFO_0003860C253416
ParagangliomaD010235144
MeningiomaD008579EFO_0003098D32.9144
PheochromocytomaD010673133
NeoplasmsD009369C80213
Merkel cell carcinomaD015266EFO_1001471C4A122
NeuroblastomaD009447EFO_0000621112
Breast neoplasmsD001943EFO_0003869C5011
Pituitary neoplasmsD01091111
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThymomaD01394511
MesotheliomaD008654C4511
GlioblastomaD005909EFO_000051511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thyroid neoplasmsD013964EFO_000384111
HyperthyroidismD006980E05.911
Stomach neoplasmsD013274EFO_0003897C1611
Gastrointestinal neoplasmsD005770C26.911
Digestive system neoplasmsD00406711
Gastrointestinal diseasesD00576711
Germ cell and embryonal neoplasmsD00937311
Endocrine system diseasesD004700EFO_0001379E34.911
Neoplasms by histologic typeD00937011
Intestinal neoplasmsD007414C26.011
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLutetium dotatate lu-177
INN
Description
Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.
Classification
Small molecule
Drug classAntineoplastic agent
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL3989924
ChEBI ID
PubChem CID
DrugBankDB13985
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 742 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,292 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use